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Abstract. Phospholipase C-~/(PLC~/) is required for 
EGF-induced motility (Chen, P., H. Xie, M.C. Sekar, 
K.B. Gupta, and A. Wells. J. Cell Biol. 1994. 127:847- 
857); however, the molecular basis of how PLC~/modu- 
lates the actin filament network underlying cell motility 
remains undetermined. We propose that one connec- 
tion to the actin cytoskeleton is direct hydrolysis of 
PIP  2 with subsequent mobilization of membrane-asso- 
ciated actin modifying proteins. We used signaling- 
restricted EGFR mutants expressed in receptor-devoid 
NR6 fibroblast cells to investigate whether EGFR acti- 
vation of PLC causes gelsolin mobilization from the cell 
membrane in vivo and whether this translocation facili- 
tates cell movement. 
Gelsolin anti-sense oligonucleotide (20 p,M) treat- 
ment of NR6 ceils expressing the motogenic full-length 
(WT) and truncated c' 1000 EGFR decreased endoge- 
nous gelsolin by 30--60%; this resulted in preferential 
reduction of EGF (25 nM)-induced cell movement by 
>50% with little effect on the basal motility. As 14 h of 
EGF stimulation of cells did not increase total cell 
gelsolin content, we determined whether EGF induced 
redistribution of gelsolin from the membrane fraction. 
EGF treatment decreased the gelsolin mass associated 
with the membrane fraction in motogenic WT and 
c'1000 EGFR NR6 cells but not in cells expressing the 
fully mitogenic, but nonmotogenic c'973 EGFR. Block- 
ing PLC activity with the pharmacologic agent U73122 
(1 ~M) diminished both this mobilization of gelsolin 
and EGF-induced motility, suggesting that gelsolin mo- 
bilization is downstream of PLC. Concomitantly ob- 
served was reorganization of submembranous actin fil- 
aments correlating directly with PLC activation and 
gelsolin mobilization. In vivo expression of a peptide 
that is reported to compete in vitro with gelsolin in 
binding to PIP2 dramatically increased basal cell motil- 
ity in NR6 cells expressing either motogenic (WT and 
c'1000) or nonmotogenic (c'973) EGFR; EGF did not 
further augment cell motility and gelsolin mobilization. 
Cells expressing this peptide demonstrated actin reor- 
ganization similar to that observed in EGF-treated con- 
trol cells; the peptide-induced changes were unaffected 
by U73122. These data suggest that much of the EGF- 
induced motility and cytoskeletal alterations can be re- 
produced by displacement of select actin-modifying 
proteins from a PIP2-bound state. This provides a sig- 
naling mechanism for translating cell surface receptor- 
mediated biochemical reactions to the cell movement 
machinery. 
TIVATION of the epidermal  growth factor receptor 
(EGFR)  and  other  receptors  with  intrinsic  ty- 
rosine kinase activity (RPTK) enhances cell motil- 
ity of many cell types contributing to organ development 
and wound repair under normal conditions and to tumor 
invasiveness in pathologic signaling  states.  Cells achieve 
movement by extending peripheral lamellipodia which re- 
quires actin reorganization  at the submembranous local- 
ization.  However,  the  translation  of  receptor-activated 
biochemical processes into the restructuring  of the actin 
cytoskeleton network remains undetermined. 
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Phospholipase  C-~/ (PLC',/) 1 activation  is  required  for 
EGF- (10) and PDGF-induced (30) motility and has been 
implicated in IGF-l-induced cell motility (7). The molecu- 
lar basis of how PLC-,/modulates the actin filament net- 
work underlying cell motility (52) is not well-understood. 
PLC activity may promote  cell  motility  secondary to  a 
generation of second messengers or by altering the mem- 
brane-cytoskeleton associations. Inositol trisphosphate  (IP3) 
and  diacylglycerol (DAG)  are produced upon PIP2 hy- 
drolysis. IP3 excites intracellular calcium release channels 
and  causes  a  transient  increase  in  intracellular  calcium 
1. Abbreviations used in this paper. DAG, diacylglycerol; EGFR, epider- 
mal growth factor receptor; PLC-% phospholipase C-~/; PPI, phospho- 
inositide. 
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though it has been controversial as to whether these intra- 
cellular calcium transients promote or inhibit actin assem- 
bly (3,  15, 33, 51),  it is widely accepted that the calcium 
transients can modulate cell movement by activating pro- 
teins involved in cytoskeletal dynamics (22, 26). However, 
calcium transients have been demonstrated not to be re- 
quired for cell motility under all conditions (19,  24, 46). 
DAG is a potent activator of members of the ser-thr ki- 
nase PKC family and exerts most of its effects through 
these kinases. Activation of PKC causes phosphorylation 
and activation of numerous regulators of the actin-cyto- 
skeleton (1, 20, 39, 48).  The effects on cell motility, how- 
ever, are pleiotropic and seem to be tissue-, cell-, and iso- 
type specific (2,  12, 62).  Independent of PKC activation, 
DAG itself has also been shown to enhance actin filament 
assembly by increasing de novo formation of action nucle- 
ation  sites  (47).  Alternatively, activated  PLC~/  initiates 
rapid turnover of polyphosphoinositides which can affect 
the distribution and activities of actin-modulating proteins 
such as profilin, CapG, and gelsolin (18, 28, 29, 32, 53, 64). 
A  number of proteins that modulate actin cytoskeleton 
organization and connection to the membrane can bind to 
PIP2.  Gelsolin  can  sequester  and  nucleate  monomeric 
G-actin as well as cap and sever polymerized F-actin; these 
functions provide a central role for gelsolin in controlling 
cell movement (11, 52, 54, 61). Gelsolin has been demon- 
strated to bind to PIP2 (29),  the substrate for PLC~/. The 
phosphoinositide  (PPI)-binding motifs in  these  proteins 
are well-conserved (50, 63, 64).  Upon PPI binding, the 
F-actin severing capacity of gelsolin family members is in- 
hibited (28, 29, 56, 64) presumably due to the interference 
with the two actin-binding sites in close proximity (28). In 
addition, peptides derived from these PIP2-binding motifs 
can compete gelsolin off PIP2-containing lipid micelles in 
vitro (28). Binding of PIP2 to profilin, another actin-modi- 
fying protein, has been shown to inhibit hydrolysis of PIP2 
by PLC-,/-1. However, EGFR-activated PLC~-I can over- 
come this inhibition, hydrolyze PIP2, and release profilin 
(18). The released profilin and gelsolin from PIP2-contain- 
ing lipid micelles regain their  actin-modulating capacity 
(17,  18, 64). These biochemical events suggest a  role for 
gelsolin and other PIP2-binding molecules in vivo to con- 
nect the RPTK-activated phospholipid cycle to actin re- 
modeling. The implication of gelsolin's role in modulating 
cell motility comes from experiments that regulate in vivo 
expression of gelsolin. Cells lacking gelsolin demonstrate 
reduced motility while overexpression of gelsolin increases 
cell movement (11, 61). 
In this study, we provide evidence that at least part of 
EGF receptor-mediated motility is actuated by gelsolin. 
Down-regulation of gelsolin in receptor-expressing NR6 
fibroblasts abrogates EGF-induced motility. We used sig- 
naling-restricted EGF receptors to decipher the signaling 
mechanisms that translate  receptor  signaling into actin- 
cytoskeleton reorganization required for cell movement. 
Only those EGF receptors that elicit cell motility caused a 
PLC-y-dependent dissociation of gelsolin from the plasma 
membrane.  Submembranous  actin-cytoskeleton changes 
were observed in parallel with this dissociation event. Fi- 
nally, cells expressing a  peptide  that encodes the  PIP2- 
binding  domain  of  gelsolin  demonstrated  cytoskeletal 
changes similar to those observed in the presence of EGF. 
The expression of this peptide also increased cell motility, 
replacing the EGF-induced motility response. 
Materials And Methods 
Expression  of Signaling-restricted EGFR in NR6 Cells 
Design and generation of the EGFR constructs and stable expression in 
NR6 cells were by standard methods, and have been described previously 
(9, 58). WT EGFR is a  full-length eDNA (55) derived from a  placental 
eDNA  library  (59).  c'973  and  c'1000  represent  EGFR  in  which  stop 
codons are introduced just distal to the amino acid number indicated. All 
three EGFR constructs present ligand-activated kinase and signal mito- 
genesis but only WT and c' 1000 promote cell motility (9). 
The constructs were expressed on NR6 cells, 3T3 derivatives that lack 
endogenous receptors (41). This was accomplished by retrovirus-mediated 
transduction as previously described  (57).  Polyclonal lines were  estab- 
lished by selection in G418 (GIBCO BRL, Gaitbersburg, MD). The infec- 
tant cell lines presented high, but physiologic levels of receptors (50,000- 
250,000 EGF-binding sites per cell) with similar dissociation constants (Kd 
were 0.2-0.7nM). 
Cell Migration Assay 
EGF-induced migration was assessed by the ability of the cells to move 
into an acellular area as previously described (9, 10).  Briefly, NR6 cells 
were plated on plastic and grown to confluence in MEMa with 7.5% FBS. 
After 24 h of incubation in media with 1% dialyzed FBS, an area was de- 
nuded by a  rubber policeman at the center of the plate. The cells were 
then treated with or without 25 nM EGF and incubated at 37°C.  Photo- 
graphs were taken at 0 and 24 h and the relative distance traveled by the 
ceils at the aceUular front was determined. The EGF-induced migration 
was calculated as a percent of basal motility observed in the non-EGF- 
treated cells tested in parallel at each time point. Mitomycin-C (0.5 sg/ml) 
was present throughout the motility assays to avoid interference from the 
mitogenic response. 
In the anti-sense oligonudeotide experiments, cells were treated for 14 h 
with or without a 21-mer oligonucleotide complementary to the transcrip- 
tion start site (5'thio-CTCCACCACCATAGTGCTGG-thio-G3') of the 
mouse gelsolin coding sequence (13). A scrambled 21-mer oligonucleotide 
(5'thio-CGGAGGAAGAAGATFGCCCTG-thio-3') controlled for spec- 
ificity of gelsolin down-regulation. Oligonucleotides (20 p,M)  were  dis- 
solved in culture medium and introduced 8 h before the addition of EGF 
(25 nM) and remained present through the entire assay period. 
In PLC inhibition assays, the pharmacological agents, U73122 (1-(6- 
((1713-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-lH- pyrrole-2,5- 
dione)  and  its  inactive  congener,  U73343  (1-(6-((lTp-3-methoxyestra- 
1,3,5(10)-trien-17-yl)amino)hexyl)-2,5-pyrrolidine-dione), were added to 
the cells to inhibit PLC activity (10).  U73122 is a relatively specific inhibi- 
tor for most PLC species (5, 10, 49) but does not inhibit PLA isoforms or 
PLD (our unpublished data). These compounds were introduced at 1 ~tM 
into the media 15 min before the addition of EGF. 
Western Blot Analyses 
In anti-sense oligonucleotide experiments, 3  x  105 cells were treated for 
14 h  with or without the 21-mer oligonucleotide complementary to the 
transcription start site of the mouse gelsolin coding sequence (see above). 
Total cell lysates were loaded in each lane. After PAGE and transfer to a 
PVDF  membrane,  two  different  polyclonal  antisera  (RaGEL-P,  East 
Acres and the generous gift of D. Kwiatkowski, Harvard University [61]) 
specific for gelsolin detected the cellular 87-kD form of gelsolin. This was 
visualized with an AP- or HRP-conjugated secondary antibody followed 
by development with colorimetric (Promega Corp., Madison, WI) or ECL 
(Amersham Corp., Arlington Heights, IL) methods. 
To determine whether EGF induces gelsolin levels, 3 x  105 cells were 
treated for 14 h with or without EGF (25 nM) before probing for gelsolin 
as above. 
Plasma Membrane Isolation 
Plasma  membrane  fractions  were  isolated  using previously  described 
methods (21).  Cells were swollen with a  hypotonic buffer and mechani- 
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centrifugation.  PMSF  (1  mM),  leupeptin  (200  p~M), bestatin  (20  ~.M), 
aprotinin (5 ~g/ml), pepstatin A  (2 ~M), and methylamine chloride (30 
nM) were present in all solutions throughout the isolation procedures to 
prevent protein degradation and the entire procedure  (~5  h) was per- 
formed on ice or at 4°C. The isolated plasma membrane fraction were 
equalized for cell number before loading on SDS-acrylamide gel and pro- 
tein content in each fraction were determined by Bradford method. In ad- 
dition, actin content in each membrane fraction was determined by immu- 
noblotting with  anti-actin  antibodies  (A2066;  Sigma Chemical Co.,  St. 
Louis, MO). The amount of gelsolin present in the membrane was deter- 
mined by immunobloning described above. 
Actin Filament Staining 
Cells were plated on coverslips and quiesced in 1% dialyzed FBS for 24 h. 
After treatment, cells were fixed for 20 rain with 3% paraforrnaldehyde in 
PBS followed by two washes with PBS. Ceils were stained for 30 min with 
2.0  U/100  Ixl rhodamine-conjugated phalloidin  (Molecular  Probes,  Eu- 
gene, OR). After two washes with PBS, coverslips were mounted on slides 
and cells were examined microscopically and photographed using a (Axio- 
vert 10; Carl Zeiss, Inc., Thornwood, NY) microscope equipped for phase 
and epifluorescence. In inhibition studies, U73122 was added 15 min be- 
fore addition of EGF. 
Expression of the Peptide Encoding PIP2-binding 
Sequence of Gelsolin 
cDNA encoding the amino acid sequence corresponding to PIP2-binding 
region of routine gelsolin (ATGCAGAGACTCITCCAGGTCAAAGG- 
GCGGCGTGTG) was cloned into the pXf vector for expression (10). A 
second cDNA fragment (ATGGCCCTCTTCTGGGTCGACGGGCTC- 
CGTGTG) encoding a  peptide  of same amino acid length was used as 
control.  Subcloning placed the cDNAs fragment under the control of a 
SV-40 early promoter present in the pXf vector.  A  DHFR  gene tran- 
scribed  from  a  second  SV-40  early  promoter  serves as  the  seleetable 
marker.  These expression vectors were  transfected using lipofectin  re- 
agent (GIBCO BRL) and stable transfectants selected in 400 mM metho- 
trexate. 
Results 
Gelsolin Is Required  for EGFR-mediated Cell Motility 
Cell  motility  is  positively  correlated  to  cellular  gelsolin 
content (11, 61). To determine if EGFR-mediated motility 
is dependent on gelsolin, we used EGFR-devoid fibroblast 
cells (NR6) expressing signaling-restricted EGFR (9, 10). 
A  full-length  (WT) EGFR  and  a  carboxy-terminal trun- 
cated EGFR which contains a single autophosphorylation 
motif (c'1000) can activate PLC~ and signal cell motility, 
while a  nonautophosphorylated  truncated  EGFR  (c'973) 
cannot (10). The infectant NR6 cells were exposed to anti- 
sense  oligonucleotides  complementary to  the  translation 
start site of the murine gelsolin coding sequence. The anti- 
sense treatment down-regulated endogenous gelsolin lev- 
els  30-60%  in  WT,  c'1000,  and  c'973  EGFR-expressing 
cells as determined by immunoblotting with quantification 
by densitometry (Fig.  1 A). A  corresponding decrease in 
EGF-induced cell motility was observed in the treated WT 
and c'1000 EGFR NR6 cells (Fig. 1 B). Basal cell motility 
was only marginally affected. A  scrambled oligonucleotide 
served as a control in half the experiments, and did not af- 
fect  endogenous  gelsolin  expression  or  cell  motility  re- 
sponse. The anti-sense treatment had little  effect on cell 
motility  in  the  nonmotogenic  c'973  EGFR-expressing 
cells. These observations suggest a requirement for gelso- 
lin in EGFR-mediated cell movement. 
To determine if EGF enhances cell motility by increas- 
ing gelsolin levels, we examined total cell gelsolin content 
after  EGF  treatment.  We  did  not  note  higher  levels in 
NR6 cells expressing either the motogenic WT and c' 1000 
EGFR or the nonmotogenic c'973 EGFR after 14 h treat- 
ment with EGF  (Fig.  2).  Therefore, it was unlikely that 
EGF promotes cell motility by increasing cellular gelsolin 
levels;  rather,  EGF  may induce  cell  motility by altering 
gelsolin subcellular distribution or activity. 
Gelsolin Dissociates  from Plasma Membrane upon 
PLC  y Activation 
In vitro, the activities of various actin modifying proteins 
are  diminished  when  bound  to  PIP2  (17,  18,  28,  64). 
EGFR-phosphorylated  PLC~t  can  cleave  PIP2,  release 
these gelsolin and profilin from PIP2-containing lipid mi- 
celles,  and  restore  gelsolin F-actin-severing activity  (17, 
18, 64). To determine whether EGF causes a similar alter- 
ation in the membrane-associated of gelsolin in vivo, we 
Figure 1.  Effects on endoge- 
nous  gelsolin  levels  and  in- 
hibits  EGF-induced  cell 
movement of anti-sense  oli- 
gonucleotide  treatment.  (A) 
Composite  immunoblot 
showing endogenous expres- 
sion  of gelsolin  in signaling- 
restricted  EGFR-expressing 
NR6 cells. Shown are repre- 
sentative  experiments  per- 
formed four times with each 
cell line. Densitometric read- 
ings are shown below the im- 
munoblot (calculated  as per- 
cent of untreated member of 
each pair).  (B)  In vitro cell 
movement in EGFR-expressing cells expressed as percent of basal cell movement. Individual experimental points were performed in trip- 
licate; values are mean _+ SEM; n  = 2-4. P  <  0.03 for EGF-induced motility between control and gelsolin anti-sense  oligonucleotide 
treatment in WT- and c'1000 EGFR-expressing cells.  P  >  0.3 between control and gelsolin anti-sense  oligonucleotide  treatment in 
c'973 EGFR expressing--cells. II, -; [], EGF. 
Chen et al. Gelsolin in EGF Receptor-mediated  Motility  691 Figure 2.  Endogenous gelsolin expression after 14 h  treatment 
with EGF. Shown is one of four experiments with similar results. 
Densitometric  readings  for this  immunoblot  are  shown below 
(calculated as percent of untreated member of each pair). 
isolated plasma membranes from the NR6 sublines. Plasma 
membranes  were  isolated  by  differential  centrifugation 
methods  described  above,  The  absence  of  cytoplasmic 
contamination of the plasma membrane preparations  was 
demonstrated  by lack  of both  LDH  activity  and  immu- 
noreactivity with anti-pan erk antibodies in parallel mem- 
brane fractions (data not shown). Amounts of membrane 
loaded on the gel were equalized for cell number. Protein 
content  in  each  fraction  was  measured  by the  Bradford 
method;  differences  among  various  treatments  were 
within 10%  (data not shown). In addition, we determined 
the actin content in the membrane fraction to control for 
variation  in  membrane  isolation  procedure  by immuno- 
blotting with anti-actin antibody. We did not observe a dif- 
ference  in  actin  content  in  the  plasma  membrane  upon 
EGF treatment (Figs. 3 and 4), 
In the presence  of EGF,  we observed  a  significant de- 
crease  in  the  gelsolin  content  of the  plasma  membrane 
fraction  of  cells  expressing  the  motility-responsive  WT 
and c'1000 EGFR (Fig. 3); a concomitant increase in cyto- 
solic gelsolin was not noted because the membrane-associ- 
ated  gelsolin  constitutes  only  a  small  fraction  of  total 
gelsolin  (data  not  shown).  This  decrease  in  membrane- 
associated  gelsolin was not observed in the non-motoge- 
nic,  non-PLC~/  activating  c'973  EGFR  expressing  cells 
(Fig. 4). 
If this dissociation of gelsolin from the membrane frac- 
tion was due to PLC~/activation, disruption of this signal- 
ing  pathway  should  prevent  the  dissociation.  The  cells 
were pretreated with U73122 (15 min), a selective PLC in- 
hibitor (10), before addition of EGF. U73122 inhibited the 
Figure 3.  Effect of EGF and PLC inhibitor U73122  on plasma 
gelsolin content  in  cells  expressing  motility-responsive,  PLC-,c- 
activating EGFR. Immunoblot demonstrating membrane-associ- 
ated gelsolin  in WT- and c'1000 EGFR-expressing NR6 cells in 
the presence (E) or absence (-) of EGF or EGF and U73122 (E/ 
U). Representative immunoblots are shown; n = 2-4 for each cell 
line; amounts loaded on gel were equalized for cell number; the 
differences in protein content of the membrane fraction among 
various treatments were within  10%. Middle panel shows the im- 
munoblot for actin present in each membrane fraction. Densito- 
metric  readings  for gelsolin  content  are  shown  in  the  bottom 
panel (calculated as percent of untreated within each cell line). 
EGF-induced decrease in plasma membrane gelsolin con- 
tent  (Fig. 3)  and decreased, in parallel,  the EGF-induced 
cell movement in the motility-responsive  WT and c'1000 
lines  (Fig.  5).  U73343,  an inactive  congener for U73122, 
also was tested  in  parallel  as  a  control; the  results  were 
identical  to  those  observed  in  cells  with  no  treatment. 
These findings strongly suggest that PIP2 hydrolysis is im- 
portant  for  gelsolin  association  with  the  plasma  mem- 
brane. 
EGF-induced Gelsolin Mobilization  and Cell 
Motility Is Accompanied by Reorganization  of the 
Actin Cytoskeleton 
To ascertain the functional consequences of EGFR-medi- 
ated signals on the actin cytoskeleton, actin filaments (F-actin) 
were  visualized  with  rhodamine-conjugated  phalloidin 
(Fig. 6). Quiescent WT cells exhibited abundant elongated 
F-actin  stress  fibers  extending  to  the  cell  membrane. 
Within 10 min of exposure to EGF, the actin cytoskeleton 
demonstrated reorganization.  In the protruded lamellipo- 
dia, stress fibers did not extend to the membrane; rather, 
short  actin  filaments  had  formed  into  submembranous 
arcs (Fig.  6). These changes persisted  throughout  12 h  of 
EGF  treatment,  corresponding  to  the  time  frame  over 
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PLC  inhibitor  U73122  on 
plasma  gelsolin  content  in 
cells expressing motility non- 
responsive,  non-PLC~/-acti- 
vating c'973 EGFR. The ex- 
perimental  design  and 
presentation is as per Fig. 3. 
A  representative  immuno- 
blot is shown; n = 4. 
which we measure cell motility (9). Parallel to these sub- 
membranous  actin  arcs  were  membrane  ruffles  as  ob- 
served  by phase  contrast  microscopy (Fig.  7).  Cells  ex- 
pressing  the  nonmotogenic  c'973  EGFR  demonstrated 
neither the subterminal foreshortened stress fibers nor the 
submembranous actin arcs (Fig. 6). The cytoskeletal struc- 
ture in the c'973 cells reflected EGF-induced lamellipodia 
retraction previously reported (59). 
The cytoskeletal reorganization in WT-expressing cells 
was dependent on PLC~/activation. U73122 prevented the 
appearance of EGF-induced lamellipodia protrusions with 
the submembranous actin arcs (Figs. 6  and 7). However, 
these  cells demonstrated  the  contracted  phenotype.  To- 
gether, these  data  demonstrate  a  causal relationship  be- 
tween EGF-induced PLC~/activation with release of gelso- 
lin from the plasma membrane and remodeling of the actin 
cytoskeleton in  the  submembrane  region  of cell  protru- 
sions. 
Figure 5.  Effect of EGF and PLC inhibitor U73122 on cell motility 
response in cells expressing EGFR constructs.  Individual experi- 
mental points were performed in triplicate;  values are mean - 
SEM;  n  =  2-4.  P  <  0.03 for EGF-induced  motility between 
U73122 treated and nontreated or U73343-treated  cells express- 
ing  WT and  c'1000  EGFR;  P  >  0.3  in  cells  expressing  c'973 
EGFR. mR, -, [], E, i, U/E. 
Expression of  a Peptide Encoding a PIP2-binding 
Sequence Mimics EGF-induced Gelsolin Dissociation 
from the Plasma Membrane and the Induced Cell 
Motility Response 
The preceding experiments suggested that PIP2 hydrolysis 
with release of gelsolin from a membrane association me- 
diates at least part of EGFR-activated motility. However, 
the observed gelsolin dissociation and cytoskeletal reorga- 
nization  may  be  secondary  to  induced  cell  motility.  A 
causal relationship between gelsolin translocation and cell 
motility  would  be  established  if  direct  mobilization  of 
gelsolin resulted in augmented cell motility. Gelsolin binds 
to PIP2 via motifs in its NH2-terminal domains which are 
loosely conserved among many actin-modifying proteins 
(Table I) (28,  64).  To test the  prediction  that release of 
gelsolin and other actin-modifying proteins from the mem- 
brane enhances motility, we expressed such a  peptide in 
the NR6 cells. We transfected a eDNA construct which en- 
codes MRLFQVKGRRV  (corresponding to amino acids 
135-146  in  murine  gelsolin  [13])  into  WT,  c'1000,  and 
c'973  EGFR-expressing  NR6  cells.  A  second  construct 
serves  as  control  peptide;  MALFWVDGLRV  was  en- 
coded because it has been demonstrated that both the pri- 
mary and secondary structure of the peptides are impor- 
tant  in  PIP2  binding  in  addition  to  the  electromagnetic 
interaction among charged molecules (28). 
In the WT- and c'1000 EGFR-expressing cells, expres- 
sion of the competitive peptide augmented the basal cell 
motility (Fig. 8 A).  In the  c'973  EGFR-expressing cells, 
expression  of  the  competitive  peptide  also  augmented 
basal  cell  movement to  a  level  comparable  to  that  ob- 
served in WT or c'1000 cells; the percent increase, how- 
ever, was not as prominent since c'973 cells present higher 
basal motility (9, 10). If EGF enhances cell motility via re- 
lease of actin-modifying proteins from the membrane then 
the competitive peptide would be predicted to blunt  the 
EGF response. EGF exposure did not further enhance cell 
motility in WT and c'1000 cells expressing the competitive 
peptide. 
The level of gelsolin which  associated with membrane 
fractions was significantly reduced in WT EGFR cells ex- 
pressing the PIP2 peptide compared with cells expressing 
the  control peptide  (Fig.  8 B).  EGF exposure decreased 
the  plasma membrane  gelsolin  content  only in  cells  ex- 
pressing the control peptide. Thus, the expression of this 
PIP2  peptide  mimicked EGF-induced  gelsolin  mobiliza- 
tion and cell motility responses. 
Expression of the Peptide Encoding 
PIP2-binding Sequence Mimics EGF-induced 
Cytoskeletal Reorganization 
The  cytoskeletal  structure  of  cells  expressing  the  PIP2 
peptide was examined. Cells expressing the PIP2 peptide 
demonstrated protruding lamellipodia lacking stress fibers 
and  the  formation  of  submembranous,  short,  thin  fila- 
ments even in  the  absence of EGF  stimulation  (Fig.  9). 
This morphology mimicked what was induced by EGF in 
control cells (Figs. 6 and 7). EGF did not further accentu- 
ate the cytoskeletal phenotype. U73122  did not alter the 
actin  reorganization,  suggesting  that  the  mobilization  of 
gelsolin was downstream of PLC activities. Cells express- 
Chen et al. Gelsolin in EGF Receptor-mediated  Motility  693 Figure 6.  Effect of EGF and PLC inhibitor U73122 on actin cytoskeleton reorganization demonstrated by rhodamine-phalloidin  stain- 
ing WT- and c'973 EGFR-expressing NR6 cells were treated with EGF (25 nM) in the absence or presence of U73122 (1 I~M) and ana- 
lyzed by rhodamine-phalloidin staining after various times. Cells shown represent the predominant morphology for each treatment, n i> 3. 
Bar, 10 Ixm. 
ing  control  peptide  responded  identically  to  nontrans- 
fected cells in cell motility, gelsolin mobilization and cy- 
toskeletal changes (Fig. 8, A and B and Fig. 9). 
Discussion 
Our data strongly suggest that EGFR-mediated cell motility 
is actuated, at least in part, by mobilization of membrane- 
associated gelsolin. We have demonstrated that dissocia- 
tion of gelsolin from the membrane parallels EGF-induced 
motility and actin reorganization, which is seen only upon 
activation of motogenic EGFR. Signaling-restricted EGFR 
were used to sort through the pleiotropic cell responses. 
c'1000 EGFR, which contain a single phosphotyrosine mo- 
tif, signal this cell event, while nonmotogenic c'973 EGFR, 
which are fully mitogenic and induce lamellipodia retrac- 
tion  (59),  promote  neither gelsolin dissociation nor sub- 
membrane  cytoskeletal  reorganization.  EGFR-mediated 
gelsolin mobilization is dependent on and downstream of 
PLC',/activation. In addition, direct dissociation of gelso- 
lin,  and  presumably other PIP2-binding  actin modifying 
proteins, mimics the EGFR-mediated cell motility and ac- 
tin reorganization responses. Thus, we can envision a mo- 
togenic signaling pathway which leads from receptors with 
intrinsic tyrosine kinase activity, via activation of PLC% to 
direct cytoskeletal reorganization required for cell motility. 
The intracellular level of gelsolin has  been correlated 
with cell motility (11, 61). Here we observed a parallel re- 
The Journal of Cell Biology, Volume 134, 1996  694 Figure 7.  Actin cytoskeleton  reorganization  demonstrated by rhodamine-phalloidin  staining and corresponding membrane ruffles by 
phase contrast in the presence of EGF and U73122. WT EGFR-expressing  NR6 cells were treated with EGF (25 nM) in the absence or 
presence of U73122 (1 IxM) and analyzed by rhodamine-phalloidin  staining after various times. Cells shown represent the predominant 
morphology  for each treatment, n 1> 3. Double arrows designate membrane Wff6s. Bar, 10 Ixm. 
duction in EGF-induced motility and endogenous gelsolin 
level upon gelsolin anti-sense oligonucleotide treatment. It 
is possible, though unlikely, that the coincident decrease in 
cellular  gelsolin  content  and  EGF-induced  cell  motility 
was due to nonspecific effects of hybrid DNA-RNA mole- 
cules generated by anti-sense treatment. The decrease in 
gelsolin content was specific for the gelsolin-complemen- 
tary oligonucleotide, as gelsolin content was still decreased 
when compared with a  control oligonucleotides comple- 
mentary to phospholipase C~/-1 (data not shown). The out- 
sized  decrease  in  motility for  a  30-450% diminution  in 
gelsolin is consistent with a model in which the majority of 
gelsolin is not PIP2 bound but rather in a cytosolic local- 
ization. If the on-rate of gelsolin for PIP2 is substantially 
less than for actin (as has been shown for profilin [18, 34]), 
then a decrease in total endogenous gelsolin is likely to be 
reflected as a preferential loss of PIP-associated (and perhaps 
motility-associated) gelsolin. Furthermore, fibroblast mo- 
tility, though decreased, is still evident in gelsolin-devoid 
fibroblasts (61). Therefore, it is likely that EGFR-medi- 
ated motility is more sensitive to gelsolin levels than basal 
cell movement. Evidence for such a model awaits an ex- 
perimentally tractable  system  in  which  cellular  gelsolin 
levels can be modulated. 
It is likely that other gelsolin-independent mechanisms 
also  are  necessary for eliciting  the  motogenic response 
since non-stimulated cells in our model system and gelso- 
lin-deficient fibroblasts (61) demonstrate basal cell move- 
ment. These mechanisms may involve both additional sig- 
naling  pathways  and  altered  activation  of  other  actin 
modifying proteins. The dissociation of gelsolin from the 
membrane fraction observed upon PLC~/  activation may 
represent a general regulatory mechanism modulating func- 
tioning of other PIP2-binding, actin-modifying proteins. 
It was surprising that the PIP2-binding peptide induced 
cell motility in the absence of EGFR signaling as motility 
is an asymmetric cell response. Nonhomogenous subcellu- 
lar distribution and differential activation of the cell motil- 
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and Competitive Peptides 
Protein  Amino acid  Sequence 
Gelsolin  135-142  K  S  G  L  g  ¥  K  K 
Gelsolin  161-169  KL  F  Q  V  K  G  R  R 
CapG  139-147  K  L  Y  Q  V  K  G  K  K 
Villin  137-145  R  L  L  H  V  K  G  K  R 
Cofilin  13-22  K  V  F  N  D  M  K  V  R  K 
Profilin  123-136  K  C  Y  E  t,I  A  S  H  L  R  R 
PIP2peptide  MR  L  F  Q  V  K  G  R  R  V* 
Control peptide  MAL  F  W  V  D  G  L  R  V* 
Sequences  are taken from reference 64. 
* stop codon. 
ity machinery may also be required to initiate cell motility, 
While gelsolin is distributed throughout the cell (14), pro- 
filin is preferentially localized to dynamic lamellipodia in 
migrating ceils (8). Though both gelsolin and profilin have 
the capacity to promote and inhibit actin polymerization, 
under  conditions  mimicking  the  in  vivo  environment, 
gelsolin is reported to preferentially sever filamentous ac- 
tin while profilin nucleates actin monomers, the event re- 
quired for actin polymerization (16, 23). Together, mobili- 
zation of multiple PIP2-binding proteins, including CapG 
Figure 8.  Effect of PIP2-binding domain peptide  on (A) EGF- 
induced cell motility and (B) membrane association of gelsolin. 
PIP/gel denotes ceils transfected with eDNA encoding PIP2 bind- 
ing sequence (Table I). Control denotes the eDNA encoding the 
control peptide. Each treatment was performed in triplicate; val- 
ues are mean +- SEM; n = 3. The immunoblot shown here is a 
representative of three experiments. The membrane isolation of 
two independent transfected WT-expressing NR6 cell lines were 
performed in the same experiment. P < 0.01 for basal cell motil- 
ity between cells with no transfection and cells transfected with 
PIP/gel in all three cell lines expressing EGFR constructs. P > 0.3 
for cell motility between cells with no transfection and cells trans- 
fected with eDNA encoding control peptide in all three cell lines 
expressing EGFR constructs. P > 0.3 between EGF-treated and 
nontreated cells in all three PIP/gel-expressing  cell lines. 
(53)  may produce the asymmetric actin-severing and -nu- 
cleating activities in the cell, leading to increased cell mo- 
tility in  the  direction  of F-actin  generation.  Therefore, 
while gelsolin is required for EGF-induced motility (Fig. 1), 
the motility-inducing and cytoskeletal effects of the PIP2- 
binding peptides are likely mediated by multiple members 
of this functional superfamily of actin-binding proteins. 
In addition, there are published data supporting roles 
for downstream activation of PKC and cytoplasmic cal- 
cium transients in modulating cell motility. These messen- 
gers are both increased by EGF-induced activation of PLC~/. 
Calcium concentration significantly affects actin polymer- 
ization and gelsolin's actin-severing activity (27, 31),  and, 
thus may play an important role in maintaining the ho- 
meostasis  of the  actin  cytoskeleton and  the  aforemen- 
tioned basal motility. PKC has been demonstrated to par- 
ticipate in focal adhesion formation and disruption as well 
as cytoskeletal rearrangement (62). All of these structures 
are essential components for cell motility (52). 
Other signaling pathways activated by receptors with in- 
trinsic  tyrosine kinase  activity likely also  participate  in 
triggering cell motility. PDGF-[3  receptor-mediated  cell 
motility requires receptor binding and subsequent activa- 
tion  of PI-3  kinase,  another  phosphoinositol-regulatory 
enzyme (7,  30).  Small G  proteins,  such as  rac  and  rho 
transmit signals for membrane ruffling and cytoskeletal re- 
organization effected by this class of receptors (40, 43, 44, 
45).  These pathways alter phospholipid content, profile, 
and  metabolism.  Thus,  the  polyphosphoinositide  cycle 
may serve as a central point of convergence. It is unsur- 
prising that altering activities of any one arm, PLC% PI3- 
kinase, or small G-proteins, will tip the balance and induce 
or inhibit cell motility. 
Cell motility is a dynamic process involving cycles of ac- 
tin cytoskeleton disruption, polymerization, and reorgani- 
zation (52). Herein, we demonstrated for the first time the 
in vivo mobilization and potential activation of gelsolin 
upon EGF stimulation. It is reasonable to speculate that 
other actin modifying  proteins which bind to PIP2 also are 
mobilized upon PLC~/activation. In vitro profilin, gelsolin, 
and other actin modifying  proteins bind reversibly to PIP2 
with this binding limiting their activities (18, 28, 35, 36, 38). 
PLC~/hydrolysis of PIP2 releases these factors from PIP2- 
containing micelles in vitro and restores their actin-modu- 
lating capacity (17, 18, 64).  It is easy to conceive that the 
ability to modulate the actin modifying activities of this su- 
perfamily of proteins is  critical to regulate cell motility. 
Extended hydrolysis of PIP2, on the other hand, has been 
associated with diminished motility (6).  These  observa- 
tions  are  consistent  with  previous  findings  linking  PPI 
tumover with cell motility (10, 32, 37). Thus, regulated re- 
distribution of the  small amount of plasma  membrane- 
associated gelsolin and other proteins would contribute 
significantly to EGF-induced cell movement. Repeatedly 
activated PLC~/in these cells (10)  mobilizes membrane- 
associated gelsolin family members, thus allowing them to 
interact and modulate the actin cytoskeleton at the sites of 
cytoskeleton interaction with the cell membrane (47). The 
localized, subtle alterations in the ratio of plasma mem- 
brane-associated  gelsolin  to  "free",  presumably  active 
gelsolin, would be  coupled with the  rapid  and  efficient 
downregulation of activated EGFR (42, 60) and PLC (25). 
The Journal of Cell Biology, Volume 134, 1996  696 Figure 9.  Effect of PIP2-binding domain peptide on actin cytoskeleton reorganization. WT EGFR-expressing NR6 cells expressing the 
PlSP2-binding or control peptide were analyzed by rhodamine-phaUoidin staining. Cells shown are representative of the majority of cells for 
each treatment, n t> 3. Bar, 10 I~m. 
This model provides a ready mechanism underlying chem- 
otactic cell motility toward higher ligand concentrations. 
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